{"prompt": "['PREDM', 'Page 6', '11.3 Confidentiality', '43', '12.0 STATISTICAL CONSIDERATIONS', '44', '12.1 Anticipated Completion Dates', '47', '12.2 Summary of Primary and Secondary Objectives', '48', '12.3 Stopping Rules', '49', '13.0 OBTAINING INFORMED CONSENT', '49', '13.1 Informed Consent Prior to Research Interventions', '49', '13.2 Consent at Age of Majority', '49', '13.3 Consent When English is Not the Primary Language', '49', 'APPENDIX I: MATRIX FOR METFORMIN PILL COUNT', '54', 'APPENDIX II:', '55', 'APPENDIX III: SCHEDULE OF RESEARCH EVALUATIONS', '59', 'APPENDIX IV:DAST AND AUDIT QUESTIONNAIRES', '60', 'APPENDIX V:', '63', 'APPENDIX VI:BARRIERS TO MEDICATION ADHERENCE', '64', 'APPENDIX VII:DISALLOWED DRUGS ON STUDY', '66', 'Initial version, dated: 04-10-20', 'IRB approkB', \"St. Jude date Children's Research Hospital\", 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 7', '1.0 OBJECTIVES', '1.1 Primary Objective', 'The primary aim of this proposal is to establish the feasibility and safety of a 24-', 'week combined metformin + intensive lifestyle intervention among adult', 'survivors with prediabetes.', 'Primary endpoints of this trial will be adherence to 1) daily metformin', 'administration, assessed by telephone-based pill counts (Appendix I), and 2)', 'completion of required core-curriculum of the lifestyle change intervention. Safety', 'will be assessed using the Global Rating of Side Effects Burden (Appendix II),', 'which includes the Common Terminology Criteria for Adverse Events (CTCAE', 'v5.0) grade.', 'Hypothesis: Metformin will be safe and well-tolerated among adult survivors of', 'childhood cancer with prediabetes. Metformin can be successfully used in', 'combination with a digitally delivered intensive lifestyle intervention.', '1.2 Secondary Objectives', 'The secondary aim is to assess preliminary evidence for efficacy of the combined', 'metformin + intensive lifestyle intervention on glycemic control and insulin', 'resistance. Glycemic control will be measured by fasting plasma glucose (FPG)', 'and hemoglobin Alc (HbA1c) and insulin resistance measured by the', 'homeostatic model assessment (HOMA-IR) and IGF-binding protein 1 (IGF-', 'BP1; a measure of insulin sensitivity strongly correlated with euglycemic insulin', 'clamp testing).', 'Hypothesis: A combined metformin and lifestyle intervention will improve', 'measures of glycemic control and insulin resistance among adult survivors of', 'childhood cancer with prediabetes, comparing baseline to 12-week (interim) and', '24-week (study-end) timepoints.', '1.3 Exploratory Objectives', 'To assess preliminary evidence for efficacy of the combined metformin +', 'intensive lifestyle intervention on weight, other anthropometric measures, blood', 'pressure and lipid profile, physical activity (self-reported and as measured by', 'accelerometer), frailty measures, and health-related quality of life (HRQOL). We', 'will also assess diabetes development at future SJLIFE visits.', 'To assess measures of participation in the lifestyle change program as well as', 'barriers to participation and medication adherence.', 'Hypothesis: A combined metformin and lifestyle intervention will improve', 'measures of body composition (including weight loss among overweight or', 'obese survivors) and physical activity among adult survivors of childhood cancer', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 8', 'with prediabetes, comparing baseline to 12-week (interim) and 24-week (study-', 'end) timepoints. Survivors with higher participation/engagement will have', 'improved efficacy endpoints.', '2.0 BACKGROUND AND RATIONALE', '2.1 Background', 'Childhood cancer survivors are at high risk for diabetes: Compared to siblings,', 'adult survivors of childhood cancer have near twice the risk of diabetes. 2,3', 'Specific cancer treatment exposures such as corticosteroids, abdominal or', 'pancreatic radiation therapy, cranial radiation therapy and total body irradiation', '(TBI) are known to increase risk for diabetes, likely through alterations in insulin', 'resistance and/or pancreatic insulin producing capacity (Figure 1). 2,3 Compared to', 'siblings, survivors who received abdominal radiation experience a 3.5-fold', 'increase in risk of diabetes and those who received TBI a near 12-fold increase in', 'risk.\u00b2 Although no association between asparaginase and diabetes has yet been', 'identified, it is plausible that direct pancreatic injury resulting from exposure to', 'this agent or drug-induced pancreatitis (corticosteroids, asparaginase or novel', 'agents) could lead to a reduced insulin producing capacity and increased diabetes', 'risk.', 'Lifestyle/Demographic', 'Treatment', 'Obesity/lifestyle', 'Genetics', 'Exposures', 'factors', '(family history)', 'Cranial', 'Radiation', 'Compensatory', 'Corticosteroid', 'Insulin resistance', '\u00df cell', 'hyperplasia', 'Abdominal', 'Radiation', 'HSCT or TBI', '\u00df cell injury', '\u00df cell failure', 'Prediabetes', 'Asparaginase', 'Figure 1. Risk factors impacting prediabetes', 'History of', 'and diabetes in survivors of childhood cancer.', 'Type Il', 'HSCT = hematopoietic stem cell transplant; TBI = total', 'Diabetes', 'pancreatitis', 'body irradiation', 'Survivors are at high risk for cardiac morbidity and mortality: Cardiac death is', 'the leading non-cancer cause of late mortality in survivors of childhood cancer.4', 'Survivors have a near 12-fold increase risk of cardiac death relative to similar', 'age- and sex-matched US population.4 Among long-term survivors exposed to', 'cardiotoxic therapy the occurrence of modifiable cardiovascular risk factors,', 'including diabetes, portends a near-multiplicative increase in risk for major', 'cardiac events. 5 Thus, diabetes prevention could provide a significant risk', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB 00-00-00', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}